Course Information
Program Objectives
The information presented at this educational activity should improve your ability to:
- Identify the addictive patient vs. the dependent patient and use good medical practice in managing these patients who also suffer from chronic pain.
- Interpret good medical practice in managing acute postoperative pain in the opiate-dependent patient who may also suffer from chronic pain.
- Identify current management practices for pain management in the opioid-dependent patient and monitor these programs for this population.
- Describe the potential advantages and disadvantages of the opioid formulations for acute and chronic pain management.
- Disseminate information to physicians, pharmacists, and other health care practitioners regarding federal and state law concerning opioids and other prescription medications.
Target Audience
Physicians, pharmacists, physician assistants, nurse practitioners, hospital and community nurses, medical students, other heathcare providers, and lay persons involved in managing acute or chronic pain in the clinic, labor and delivery suites, and operating room, as well as in community health settings.
Accreditation
The School of Medicine of The University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit
The School of Medicine of The University of North Carolina at Chapel Hill designates this educational activity for up to 6.75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
In accordance with the ACCME Essentials and Standards, everyone involved in planning or presenting this educational activity will be required to disclose any relevant financial relationships with commercial interests in the healthcare industry, and this information will be made available to participants at the start of the activity. In addition, speakers who incorporate information about off-label or investigational uses of drugs or devices will be asked to disclose that information at the beginning of their presentaion.